{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T01:51:01Z","timestamp":1794448261378,"version":"4.9.1"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","funder":[{"name":"National Institute on Drug Abuse of the National Institutes of Health","award":["K01DA045618"],"award-info":[{"award-number":["K01DA045618"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>In 2011, the Centers for Medicare &amp; Medicaid Services implemented bundling of all services for patients receiving dialysis, including erythropoietin-stimulating agents use, and the Food and Drug Administration recommended conservative erythropoietin-stimulating agent dosing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>This retrospective cohort study investigated anemia care and clinical outcomes before and after the Centers for Medicare &amp; Medicaid Services bundled payment and the revised Food and Drug Administration\u2013recommended erythropoietin-stimulating agent labeling for Medicare-insured adults receiving hemodialysis using data from the United States Renal Data System from January 1, 2006 to December 31, 2016. Clinical outcomes included major adverse cardiovascular event (stroke, acute myocardial infarction, and all-cause mortality), cardiovascular mortality, and heart failure. Measurements were compared between prepolicy (2006\u20132010) and postpolicy (2012\u20132016) implementation using interrupted time series and Cox proportional hazards regression models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 481,564 patients, erythropoietin-stimulating agent use immediately decreased by 84.8 per 1000 persons (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001), with a significant decrease in the slope of the trend line (both\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.001). Blood transfusion use rapidly increased by 8.34 per 1000 persons in April 2012 and then gradually decreased (both\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.001). The percentage of patients with hemoglobin &gt;11 g\/dl decreased from 68% in January 2006 to 28% in December 2016, whereas those with hemoglobin &lt;9 g\/dl increased from 5% to 9%. Overall major adverse cardiovascular event (adjusted hazard ratio, 0.95; 95% confidence interval, 0.94 to 0.96), stroke (adjusted hazard ratio, 0.83; 95% confidence interval, 0.80 to 0.86), all-cause mortality (adjusted hazard ratio, 0.87; 95% confidence interval, 0.86 to 0.89), cardiovascular mortality (adjusted hazard ratio, 0.81; 95% confidence interval, 0.79 to 0.83), and heart failure (adjusted hazard ratio, 0.86; 95% confidence interval, 0.84 to 0.88) risks were lower. Acute myocardial infarction risk (adjusted hazard ratio, 1.04; 95% confidence interval, 1.01 to 1.06) was higher after policies changed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The Medicare reimbursement policy and Food and Drug Administration\u2013recommended erythropoietin-stimulating agent dosing changes were associated with lower erythropoietin-stimulating agent use and lower hemoglobin levels. These changes in anemia care were associated with lower risks of major adverse cardiovascular event, stroke, mortality, and heart failure but higher risk of acute myocardial infarction among adults receiving hemodialysis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.14361121","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T12:23:40Z","timestamp":1653308620000},"page":"851-860","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Medicare Bundled Payment Policy on Anemia Care, Major Adverse Cardiovascular Events, and Mortality among Adults Undergoing Hemodialysis"],"prefix":"10.2215","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3299-8111","authenticated-orcid":false,"given":"Haesuk","family":"Park","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida"},{"name":"Center for Drug Evaluation and Safety, College of Pharmacy, University of Florida, Gainesville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Desai","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0201-839X","authenticated-orcid":false,"given":"Steven M.","family":"Smith","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Safety, College of Pharmacy, University of Florida, Gainesville, Florida"},{"name":"Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Hincapie-Castillo","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Henry","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida"},{"name":"Center for Drug Evaluation and Safety, College of Pharmacy, University of Florida, Gainesville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie","family":"Goodin","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida"},{"name":"Center for Drug Evaluation and Safety, College of Pharmacy, University of Florida, Gainesville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saraswathi","family":"Gopal","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Florida, Gainesville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl J.","family":"Pepine","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Florida, Gainesville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4430-8678","authenticated-orcid":false,"given":"Raj","family":"Mohandas","sequence":"additional","affiliation":[{"name":"Department of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,6]]},"reference":[{"key":"B1-20241015","first-page":"38","article-title":"Bundled payment for ESRD--Including ESAs in Medicare\u2019s dialysis package","volume":"94","author":"Iglehart","year":"2011","journal-title":"Minn Med"},{"key":"B2-20241015","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.ajkd.2017.09.026","article-title":"Update on anemia in ESRD and earlier stages of CKD: Core curriculum 2018","volume":"71","author":"Fishbane","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"B3-20241015","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1377\/hlthaff.2012.0368","article-title":"Medicare\u2019s payment strategy for end-stage renal disease now embraces bundled payment and pay-for-performance to cut costs","volume":"31","author":"Swaminathan","year":"2012","journal-title":"Health Aff (Millwood)"},{"issue":"Suppl 3","key":"B4-20241015","first-page":"S192","article-title":"NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure","volume":"30","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"B5-20241015","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"B6-20241015","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Dr\u00fceke","year":"2006","journal-title":"N Engl J Med"},{"key":"B7-20241015","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"B8-20241015","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"key":"B9-20241015","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2004121039","article-title":"Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease","volume":"16","author":"Parfrey","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B10-20241015","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/sj.ki.5002401","article-title":"The new FDA label for erythropoietin treatment: How does it affect hemoglobin target?","volume":"72","author":"Fishbane","year":"2007","journal-title":"Kidney Int"},{"key":"B12-20241015","first-page":"70228","article-title":"Medicare program; end-stage renal disease prospective payment system and quality incentive program; ambulance fee schedule: Durable medical equipment; and competitive acquisition of certain durable medical equipment, prosthetics, orthotics an supplies: Final rule","volume":"76","year":"2011","journal-title":"Fed Regist"},{"key":"B13-20241015","first-page":"12","article-title":"Bundling and its potential impact on dialysis service providers","volume":"22","author":"Sullivan","year":"2008","journal-title":"Nephrol News Issues"},{"key":"B14-20241015","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","article-title":"Segmented regression analysis of interrupted time series studies in medication use research","volume":"27","author":"Wagner","year":"2002","journal-title":"J Clin Pharm Ther"},{"key":"B15-20241015","first-page":"348","article-title":"Interrupted time series regression for the evaluation of public health interventions: A tutorial","volume":"46","author":"Bernal","year":"2017","journal-title":"Int J Epidemiol"},{"key":"B17-20241015","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group","volume":"17","author":"D\u2019Agostino","year":"1998","journal-title":"Stat Med"},{"key":"B18-20241015","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1159\/000370334","article-title":"Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status","volume":"40","author":"Thamer","year":"2014","journal-title":"Am J Nephrol"},{"key":"B19-20241015","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/1475-6773.12252","article-title":"Effect of Medicare dialysis payment reform on use of erythropoiesis stimulating agents","volume":"50","author":"Swaminathan","year":"2015","journal-title":"Health Serv Res"},{"key":"B20-20241015","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1053\/j.ajkd.2013.03.044","article-title":"The initial impact of Medicare\u2019s new prospective payment system for kidney dialysis","volume":"62","author":"Hirth","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"B21-20241015","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1053\/j.ajkd.2013.09.006","article-title":"The DOPPS practice monitor for U.S. dialysis care: Update on trends in anemia management 2 years into the bundle","volume":"62","author":"Fuller","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"B22-20241015","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1053\/j.ajkd.2014.01.011","article-title":"Blood transfusion practices in dialysis patients in a dynamic regulatory environment","volume":"64","author":"Hirth","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"B23-20241015","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1053\/j.ajkd.2012.11.040","article-title":"Early trends from the Study to Evaluate the Prospective Payment System Impact on Small Dialysis Organizations (STEPPS)","volume":"61","author":"Brunelli","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"B24-20241015","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12882-016-0267-x","article-title":"Effects of the prospective payment system on anemia management in maintenance dialysis patients: Implications for cost and site of care","volume":"17","author":"Wetmore","year":"2016","journal-title":"BMC Nephrol"},{"key":"B25-20241015","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1681\/ASN.2015111232","article-title":"Epoetin alfa and outcomes in dialysis amid regulatory and payment reform","volume":"27","author":"Chertow","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B26-20241015","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1001\/jamainternmed.2016.6520","article-title":"Association between changes in CMS reimbursement policy and drug labels for erythrocyte-stimulating agents with outcomes for older patients undergoing hemodialysis covered by fee-for-service Medicare","volume":"176","author":"Wang","year":"2016","journal-title":"JAMA Intern Med"},{"key":"B27-20241015","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/ndt\/gfp396","article-title":"Considering health insurance: How do dialysis initiates with Medicaid coverage differ from persons without Medicaid coverage?","volume":"25","author":"Wetmore","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"B28-20241015","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/0002-8703(94)90679-3","article-title":"Hematocrit and the risk of cardiovascular disease--The Framingham study: A 34-year follow-up","volume":"127","author":"Gagnon","year":"1994","journal-title":"Am Heart J"},{"key":"B29-20241015","doi-asserted-by":"crossref","first-page":"e007723","DOI":"10.1161\/JAHA.117.007723","article-title":"Association of hemoglobin concentration and its change with cardiovascular and all-cause mortality","volume":"7","author":"Lee","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"B30-20241015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0735-1097(02)01938-1","article-title":"Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study","volume":"40","author":"Sarnak","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"B31-20241015","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1681\/ASN.2004070597","article-title":"Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease","volume":"16","author":"Weiner","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B32-20241015","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0002-8703(72)90445-0","article-title":"Cardiovascular effects of anemia","volume":"83","author":"Varat","year":"1972","journal-title":"Am Heart J"},{"key":"B33-20241015","doi-asserted-by":"crossref","first-page":"e193290","DOI":"10.1001\/jamanetworkopen.2019.3290","article-title":"Association between medicare policy reforms and changes in hospitalized Medicare beneficiaries\u2019 severity of illness","volume":"2","author":"Sukul","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B34-20241015","doi-asserted-by":"crossref","first-page":"e008032","DOI":"10.1161\/JAHA.117.008032","article-title":"Cardiac troponins for the diagnosis of acute myocardial infarction in chronic kidney disease","volume":"7","author":"Kraus","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"B35-20241015","doi-asserted-by":"crossref","first-page":"e191938","DOI":"10.1001\/jamanetworkopen.2019.1938","article-title":"Twenty-year trends in outcomes for older adults with acute myocardial infarction in the united states","volume":"2","author":"Krumholz","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B36-20241015","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1681\/ASN.2016101079","article-title":"The ESRD quality incentive program: Can we bridge the chasm?","volume":"28","author":"Weiner","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B38-20241015","doi-asserted-by":"crossref","first-page":"852","DOI":"10.2215\/CJN.00020112","article-title":"Effect of red cell transfusions on future kidney transplantation","volume":"8","author":"Obrador","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"B39-20241015","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/1471-2369-14-217","article-title":"An update on the impact of pre-transplant transfusions and allosensitization on time to renal transplant and on allograft survival","volume":"14","author":"Scornik","year":"2013","journal-title":"BMC Nephrol"},{"key":"B40-20241015","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.2215\/CJN.03680411","article-title":"Early outcomes among those initiating chronic dialysis in the United States","volume":"6","author":"Chan","year":"2011","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.14361121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:44:25Z","timestamp":1786369465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.14361121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.14361121","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"2021-11-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}